Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
Anna Marie Mulligan, Matti A. Rookus(The Netherlands Cancer Institute), Juul Wijnen(Memorial University of Newfoundland), Marcel Nelen(Utrecht University), Fergus J. Couch(Mayo Clinic), Theo van Os(Amsterdam UMC Location University of Amsterdam), Iván Muñoz‐Repeto(Spanish National Cancer Research Centre), Thomas van Overeem Hansen(University of Copenhagen), Barbara Pasini(University of Turin), C. Marleen Kets, Bent Ejlertsen, Siranoush Manoukian(Fondazione IRCCS Istituto Nazionale dei Tumori), Ana Osório(Spanish National Cancer Research Centre), Daniel Barrowdale(University of Cambridge), Laura Papi(University of Florence), Mark E. Robson(Memorial Sloan Kettering Cancer Center), Susan J. Ramus(Cancer Institute of New South Wales), Martijn Verheus(The Netherlands Cancer Institute), Heli Nevanlinna(University of Helsinki), Lesley McGuffog(University of Cambridge), Ramūnas Janavičius(Vilnius University), Daniela Zaffaroni(Fondazione IRCCS Istituto Nazionale dei Tumori), Susan M. Domchek(University City Science Center), Ute Hamann(German Cancer Research Center), Hanne Meijers‐Heijboer(German Cancer Research Center), Rob B. van der Luijt(Institute for Quality and Efficiency in Health Care), Bernardo Bonanni(European Institute of Oncology), Bernard Peissel(Sapienza University of Rome), Laura Ottini(Mount Sinai Hospital), M. Durán(Universidad de Valladolid), Antonella Savarese, Andrew Lee(University of Cambridge), Barbara Wappenschmidt(University Hospital Cologne), Paolo Peterlongo(IFOM), Amanda B. Spurdle(QIMR Berghofer Medical Research Institute), Paolo Radice(IFOM), Loris Bernard(European Institute of Oncology), Finn C. Nielsen(Copenhagen University Hospital), Sue Healey(QIMR Berghofer Medical Research Institute), Mark E. Sherman(National Cancer Institute), Javier Benítez(Spanish National Cancer Research Centre), Caroline Seynaeve(Erasmus MC), Madeleine M.A. Tilanus‐Linthorst(Erasmus University Rotterdam), Olga M. Sinilnikova(Hospices Civils de Lyon), Elisa Cattaneo(Fondazione IRCCS Istituto Nazionale dei Tumori), Diana Eccles(Princess Anne Hospital), E. Gómez(Maastricht University Medical Centre), Alessandra Viel(Centro di Riferimento Oncologico), Maroulio Pertesi(Centre international de recherche sur le cancer)
Cited by 118
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition
|New England Journal of Medicine|2004|1.7k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k